Gizelle Lopez previews her upcoming course at the ASCP 2026 Annual Meeting, “Molecular Diagnostics in Neuropathology: Choosing the Right Test, and Knowing Testing Pitfalls.”
The following transcript has been edited for clarity.
I'm Giselle Lopez, associate professor of pathology at Duke University. In this session, you will learn about critical tests used in molecular diagnostics with a focus on applications in neuropathology.
In part one, we'll discuss the basic technology and underpinnings behind tests like fluoresence in site 2 hybridization (FISH), chromosomal microarray, next-generation sequencing, and methylation profiling. Oftentimes, we have limited tissue and have to pick between tests for the same result. We'll discuss when to use sequencing versus immunohistochemistry, FISH versus chromosomal microarray, even Sanger sequencing versus next-generation sequencing. Each test has its own risks of false positives or false negatives. We'll discuss the limitations of each test and how to take those limitations into account when deciding which test to use for a given patient specimen.
In part two, we'll discuss some known pitfalls and interpretation of tests specific to neuropathology. We'll cover differences between antibodies for H3K27M, H3 K27 trimethylation, and H3G34 RV and how to interpret these antibodies. We'll discuss canonical and non-cononical variants in LDH and how to decide whether a variant makes LDH truly mutant.
In part three, we'll go through approaches to review outside next-generation testing results. Know where to look for the information that you need in a report, especially where key information may be hiding, and learn about common pitfalls in interpreting sendout molecular pathology reports.
Finally, we'll put it all together with case studies to demonstrate how to actually apply these approaches.
Looking forward to seeing you in Montréal in November.
